Madrigal Pharmaceuticals (NASDAQ:MDGL) had its target price hoisted by stock analysts at Roth Capital from $170.00 to $210.00 in a research report issued to clients and investors on Friday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Roth Capital’s price target would indicate a potential upside of 65.32% from the stock’s current price.
A number of other equities research analysts have also commented on MDGL. JMP Securities upped their target price on Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the company an “outperform” rating in a research report on Friday, October 13th. HC Wainwright started coverage on Madrigal Pharmaceuticals in a research report on Wednesday, November 29th. They issued a “buy” rating and a $54.00 target price on the stock. Evercore ISI upped their target price on Madrigal Pharmaceuticals from $65.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, December 7th. Zacks Investment Research upgraded Madrigal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $94.00 target price on the stock in a research report on Wednesday, December 20th. Finally, BidaskClub upgraded Madrigal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 20th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $154.20.
Shares of Madrigal Pharmaceuticals (NASDAQ MDGL) traded down $4.50 during mid-day trading on Friday, hitting $127.03. The stock had a trading volume of 392,933 shares, compared to its average volume of 226,280. Madrigal Pharmaceuticals has a 1-year low of $13.09 and a 1-year high of $154.75. The stock has a market capitalization of $1,780.00, a price-to-earnings ratio of -51.64 and a beta of 1.19.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. The Manufacturers Life Insurance Company boosted its position in Madrigal Pharmaceuticals by 64.9% in the fourth quarter. The Manufacturers Life Insurance Company now owns 3,553 shares of the biopharmaceutical company’s stock valued at $326,000 after buying an additional 1,399 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Madrigal Pharmaceuticals by 17.9% in the third quarter. Bank of New York Mellon Corp now owns 12,945 shares of the biopharmaceutical company’s stock valued at $582,000 after acquiring an additional 1,963 shares during the period. SG Americas Securities LLC acquired a new position in Madrigal Pharmaceuticals in the third quarter valued at approximately $100,000. Strs Ohio lifted its holdings in Madrigal Pharmaceuticals by 241.7% in the fourth quarter. Strs Ohio now owns 4,100 shares of the biopharmaceutical company’s stock valued at $376,000 after acquiring an additional 2,900 shares during the period. Finally, State of Wisconsin Investment Board acquired a new position in Madrigal Pharmaceuticals in the fourth quarter valued at approximately $275,000. Hedge funds and other institutional investors own 20.53% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Madrigal Pharmaceuticals (MDGL) PT Raised to $210.00” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/09/madrigal-pharmaceuticals-mdgl-pt-raised-to-210-00.html.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.